Adacel Vaccine Description
Adacel vaccine contains noninfectious tetanus, diphtheria, and pertussis proteins, aluminum phosphate, 2-phenoxyethanol, and residual amounts of formaldehyde and glutaraldehyde. Adacel vaccine does not contain preservatives.
Adacel Vaccine Indication
Adacel (Tdap) is indicated for active booster immunization prevent tetanus, diphtheria, and pertussis in people who are at least 10 years old through 64 years of age.
Adacel Vaccine Dosage
Adacel is administered as an intramuscular injection.
Adacel vaccine is approved for use as a single dose in individuals 10 through 64 years of age.
Most people in this age group require only one Tdap shot for protection against these diseases.
Eight years should have elapsed since the recipient’s last dose of tetanus toxoid, diphtheria toxoid, and/or pertussis-containing vaccine and the administration of Adacel vaccine.
Adacel Vaccine News
January 11, 2019 - The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria, and pertussis. It is now the first, and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years.
Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.
Adacel Vaccine Clinical Trials
Adacel has been involved in over 19 clinical studies.